Tue, Jul 22, 2014, 2:55 PM EDT - U.S. Markets close in 1 hr 5 mins


% | $
Click the to save as a favorite.

Opko Health, Inc. Message Board

  • investora2z investora2z Nov 28, 2013 12:24 PM Flag

    Has corrected...

    The stock has corrected sharply over the last 7-8 weeks. It is nearly 20% below the 52 week high made in the middle of last month. The news that Lakewood Capital had initiated a short position in the company's shares led to some pressure. Lakewood earlier had a long position in the stock. The level of shorts were at extremely high levels on October 31 and hence the stock is vulnerable to volatile movements. In case of positive news, the squeeze can be very strong. The insider and institutional holding is extremely high, and investors like Soros Fund Management have a long position in the stock. However, despite the correction, it has done great in 2013 with more than 100% appreciation. Last couple of weeks have seen some recovery, but the volumes patterns are not so supportive. Dr. Frost has made some purchases recently which has supported the positive sentiments. Dr. Frost has been active with his other companies as well, and recently Biozone Pharmaceuticals (BZNE) was merged with Cocrystal Discovery where Opko and Teva (TEVA) have a stake. The strong performance of Opko is also mainly due to the support of Dr. Frost. The numerous acquisitions have also helped build positive sentiments about the prospects of the company. Many of Opko's investments may take time to yield tangible results, and hence improvement in the fundamentals may take a few years. The valuations are primarily based on promise, and the price to sales is still exceptionally high. An article on SA was positive on the future prospects of the company based on its candidates and catalysts in the near future. The analyst considered the recent fall as a buying opportunity, especially in view of purchases by Dr. Frost from the market. Dr. Frost's continued support is surely a factor, especially if one considers the possibility of a squeeze.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Correct. There is no real conclusion. Facts are right! The risk factor is the high evaluation. The big chance is the pipeline and a realistic approval by Rayaldi and Rolapitant (out-licensed to TESARO). Tesaro will probably give us more insight at the DB Conference on Monday the 2nd. Before that the stock react positive in the last days.

      TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President of TESARO, will present at the 2013 Deutsche Bank BioFEST conference at the Four Seasons Hotel in Boston on Monday, December 2, 2013 at 2:15 p.m. Eastern time.

      Some speculation is regarding that the CEO and the President will be there and tell us some positive news on Rolaptiant. At the latest in December we will get more infos about Rolapitant. OPKO will get licence fee and a potential milestone fee.

      Sentiment: Strong Buy

    • Hmm, what's your point of the post? Seems like you are just throwing out random bits of info here and there.

      I'll disagree with the title of your post as a "correction". Some of us have been with the stock much longer than a few months. Some wacky price swings in October based off no news swung up the price up, but ignoring that swing - the price has been trending upwards. Try looking at a 1 year chart and I think you'll have a different conclusion.

    • thanks for your insight!

      Sentiment: Hold

8.646-0.034(-0.39%)2:54 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.